NCT06554587Completed
Investigation of Three Biomarkers for the Detection of Prostate Cancer
Evaluation of the Performance of the Glycoscore Biomarkers for the Detection of Clinically Significant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore biomarkers with PSA (prostate specific antigen). The results from this study will be used to identify the most suitable biomarker/biomarkers for use in developing a GlycoScore test. This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 137 (actual)
- First submitted
- 12 Aug 2024
- Start date
- 7 Jan 2025
- Primary completion date
- 7 Aug 2025
- Lead sponsor
- Medtechtomarket Consulting Ltd
- Diseases
- Prostate cancer
- NCT number
- NCT06554587
What you commit to
- Study type: Observational
- Participants enrolled: 137
- From 7 Jan 2025 to the primary completion date, 7 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient has a prior diagnosis of any other cancer or is receiving any cancer treatment (including ADT)
Other illness
- A patient with an active urinary tract infection
Other
- A patient who has already taken part in the study
- The patient is currently or within the last 4 months enrolled on another study involving an investigational medicinal product
Who the study is looking for
- Male patients aged 18 years and over
- The patient is being investigated for suspected prostate cancer or is on active surveillance
- The patient is able to give consent to take part in the study
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Liverpool University Hospital Coordinator of this site? Confirm its status | Liverpool | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.